COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case–control study

Simon J. Hong, Sumona Bhattacharya, Aiya Aboubakr, Devika Nadkarni, Diana Lech, Ryan C. Ungaro, Manasi Agrawal, Robert P. Hirten, Ruby Greywoode, Anjali Mone, Shannon Chang, David P. Hudesman, Thomas Ullman, Keith Sultan, Dana J. Lukin, Jean-Frederic Colombel and Jordan E. Axelrad on behalf of the New York Crohn's and Colitis Organization (NYCCO)

Abstract

**Background:** Inflammatory bowel disease (IBD) is not associated with worse coronavirus disease 2019 (COVID-19) outcomes. However, data are lacking regarding the long-term impact of severe acute respiratory syndrome coronavirus 2 infection on the disease course of IBD.

**Objectives:** We aimed to investigate the effect of COVID-19 on long-term outcomes of IBD.

**Design:** We performed a multicenter case–control study of patients with IBD and COVID-19 between February 2020 and December 2020.

**Methods:** Cases and controls were individuals with IBD with presence or absence, respectively, of COVID-19-related symptoms and confirmatory testing. The primary composite outcome was IBD-related hospitalization or surgery.

**Results:** We identified 251 cases [ulcerative colitis (n = 111, 45%), Crohn’s disease (n = 139, 55%)] and 251 controls, with a median follow-up of 394 days. The primary composite outcome of IBD-related hospitalization or surgery occurred in 29 (12%) cases versus 38 (15%) controls (p = 0.24) and on multivariate Cox regression, COVID-19 was not associated with increased risk of adverse IBD outcomes [adjusted hazard ratio (aHR): 0.84, 95% confidence interval (CI): 0.44–1.42]. When stratified by infection severity, severe COVID-19 was associated with a numerically increased risk of adverse IBD outcomes [aHR: 2.43, 95% CI: 1.00–5.86], whereas mild-to-moderate COVID-19 was not (aHR: 0.68, 95% CI: 0.38–1.23).

**Conclusion:** In this case–control study, COVID-19 did not have a long-term impact on the disease course of IBD. However, severe COVID-19 was numerically associated with worse IBD outcomes, underscoring the continued importance of risk mitigation and prevention strategies for patients with IBD during the ongoing COVID-19 pandemic.

**Keywords:** COVID-19, inflammatory bowel disease, long term, outcomes

Background

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative virus of coronavirus disease 2019 (COVID-19) pandemic, has infected more than 390 million people worldwide as of 1 February 2022 and continues to remain a global health crisis. Inflammatory bowel diseases (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), are chronic immune-mediated inflammatory diseases (IMIDs) of the gastrointestinal tract that often require long-term immunosuppressive therapy for management. Early in the onset of the pandemic there was concern that IBD, chronic immune dysregulation, and associated immunosuppression may represent...
TherapeuTic advances in Gastroenterology

a potential risk factor for SARS-CoV-2 infection or severe outcomes. Subsequent studies have largely shown that IBD does not increase the risk of SARS-CoV-2 infection or worse COVID-19 outcomes. Data have also confirmed that biologic and novel small molecule therapies are not associated with worse COVID-19 outcomes. Furthermore, vaccines against SARS-CoV-2 are effective in reducing symptomatic or severe COVID-19, and early data have shown that in patients with IBD, vaccine efficacy is comparable with that in the general population.

While these data are reassuring, the long-term impact of COVID-19 on the course of IBD remains largely unknown. Studies from the previous SARS epidemic of 2003 have shown a durable impact of infection with the SARS-CoV-1 virus on long-term pulmonary function, exercise capacity, psychiatric comorbidities, and chronic fatigue. Similarly, data suggest that COVID-19 is associated with long-term respiratory, neurologic, and psychiatric sequelae. Long-haul COVID-19 results in immune dysfunction that can persist up to 8 months after infection, and in the gastrointestinal tract, where angiotensin-converting enzyme 2 expression is increased and SARS-CoV-2 antigen can persist, it is associated with chronic abdominal pain, altered bowel motility, and irritable bowel syndrome. Furthermore, the cytokine storm associated with COVID-19 results in elevation of several pro-inflammatory cytokines, particularly interleukin (IL)-6, IL-10, IL-2, and IL-17, that are implicated in the pathogenesis of IBD. Given these reported associations, the possible consequence of COVID-19 is an alteration of the inflammatory milieu with a downstream deleterious impact on IBD outcomes.

In this multicenter, case–control study, we aimed to determine the impact of COVID-19 on long-term outcomes of IBD.

Methods

Study population

A multicenter, case–control, observational cohort was performed by five academic medical centers within the New York Crohn’s and Colitis Organization. After Institutional Review Board approval at each participating site, electronic medical records were reviewed to identify patients with an established diagnosis of IBD (CD, UC, or IBD-undefined) for at least 1 year who were confirmed to have COVID-19 (cases) or not (controls) between February 2020 to December 2020.

COVID-19 definitions and variables

COVID-19 cases were defined as individuals with the presence of COVID-19 symptoms (fever, cough, dyspnea, anosmia, dysgeusia, pharyngitis, diarrhea, arthralgia–myalgia/asthenia, rhinitis, dysphonia) with a confirmatory positive nasopharyngeal SARS-CoV-2 PCR test at the time of symptoms and/or subsequent positive SARS-CoV-2-IgG antibody test in 2020. Controls were individuals with the absence of COVID-19 symptoms (excluding diarrhea) and both one negative SARS-CoV-2 PCR and at least one negative SARS-CoV-2 IgG in 2020 in testing performed at the academic medical centers involved in this study. Severe COVID-19 was defined as need for hospitalization, mechanical ventilation, or intensive care unit admission. Cases and controls were matched 1:1 based on age, sex, and type of IBD. Sample size was determined by the number of all eligible cases within the study period.

We collected the following initial data on demographics and disease characteristics: age, sex, IBD disease extent and phenotype (Montreal classification), history of IBD-related surgery and/or hospitalizations, and IBD treatment history; and for cases, COVID-19 disease course and management. These data were entered into a REDCap electronic database accessible to participating centers. Long-term outcomes for each patient were then prospectively collected from April to December 2021 and updated in the REDCap database.

Outcomes

The primary outcome was a composite of IBD-related hospitalization (non-elective) or surgery at any time during follow-up. Secondary outcomes included biologic dose escalation, switch to a new biologic or small molecule therapy, corticosteroid initiation, change in UC extent, change in CD location or behavior, development of non-IBD IMID, initiation of new psychiatric care or medication, and interval COVID-19, time to first follow-up, and delay of next biologic dose. For each outcome, patients were censored at date of first outcome event, date of interval COVID-19 (if a
patient in the control group was subsequently infected), or date of last follow-up, whichever was earliest. For the primary outcome, the study groups were further stratified by COVID-19 severity (non-severe versus severe).

**Statistical analysis**
Continuous variables were summarized using means with standard deviation or medians with interquartile ranges (IQRs) and were compared using Student’s t test or Wilcoxon rank-sum test. Chi-squared tests of independence and Fischer’s exact tests were used for categorical variables between groups and Kruskal–Wallis tests for continuous variables. Missing variables were excluded from statistical analysis. Time to the primary outcome was compared between the study groups with Kaplan–Meier survival curves using log-rank analysis. Cox proportional hazards models were used to identify the risk of the primary outcome adjusted for COVID-19 severity, indicators of IBD disease severity (prior IBD hospitalization or surgery, duration of disease), disease activity (current steroids or biologic use), and delays in care (time to first follow-up or postponement of biologics). Statistical analysis was performed using IBM SPSS 25 (IBM, Armonk, NY, USA). The reporting of this study conforms to the STROBE statement.23

**Results**

**Cohort baseline characteristics**
We identified 251 patients with IBD [UC (n=112, 45%), CD (n=139, 55%)] and confirmed COVID-19 matched to 251 controls [UC (n=112), CD (n=139)]. The median age in the overall cohort was 39 years (IQR: 30–52), and 45% of patients were males (Table 1). There were no differences between study groups in age, race, ethnicity, duration of IBD, or smoking status. A total of 5642 person-months of follow-up were assessed, with a median follow-up of 417 days (IQR: 304–495; range: 43–581) for controls and 358 days (IQR: 238–459; range: 32–576) for COVID-19 cases. The majority of cases (n=208, 81%) occurred between March and May 2020.

At baseline, COVID-19 patients had higher rates of previous IBD-related hospitalizations (36% versus 27%; p=0.03), corticosteroid use (75% versus 65%; p=0.06), and biologic exposure (73% versus 64%; p=0.04) than controls (Table 1).

There were no differences in extent of UC or CD location or behavior between groups, or in prevalence of coexisting comorbidities (Supplemental Table 1). Among cases of COVID-19, 39 (16%) were severe and 212 (84%) were mild–moderate. Among patients with COVID-19, 63 (25%) had their next biologic dose delayed, with a median delay of 14 days (Supplemental Table 2). Overall, 49 (20%) patients received COVID-19-related therapy, with a higher rates of use in severe COVID-19 cases than in mild–moderate cases (72% versus 10%, p<0.001).

**Long-term primary and secondary outcomes**
The primary composite outcome of IBD-related hospitalization or surgery occurred at similar rates between COVID-19 cases (12%, n=29) and controls (15%, n=38; p=0.24; Table 2) and there was no difference in times to these outcomes (log-rank p=0.70, Figure 1). Between COVID-19 cases and controls, there were no differences in unadjusted rates of hospitalization or surgery, biologic dose escalation, switch to new biologic or corticosteroid initiation, and progression of UC or CD extent or phenotype. Control patients were more likely to subsequently receive a COVID-19 vaccine in than were cases (74% versus 51%, p<0.001). On multivariable analysis, after adjusting for prior IBD hospitalization or surgery, penetrating or stricturing CD, extensive UC, steroid use, biologic or small molecule, biologic delay, and time to first follow-up, compared to controls, COVID-19 was not associated with an increased risk of the primary composite outcome [adjusted hazard ratio (aHR): 0.84, 95% confidence interval (CI): 0.44–1.42], whereas prior hospitalization or surgery (aHR: 2.71, 95% CI: 1.53–4.80) (Table 3).

**Sub-group analysis: stratified by COVID-19 severity**
When further stratified by COVID-19 severity, the primary composite outcome occurred in 21% (8/39) of patients with severe COVID-19 compared with 11% (21/212) of those with mild-to-moderate COVID-19 and 15% (38/251) of controls (log-rank p=0.02; Supplemental Figure 1). When COVID-19 severity was included in the multivariable model described above, severe
COVID-19 was associated with a numerically increased risk of the primary composite outcome (aHR 2.43: 95% CI: 1.00–5.86), whereas mild-to-moderate COVID-19 was not (aHR: 0.68, 95% CI: 0.38–1.23; Table 4). Inclusion of administration of COVID-19 therapies in the multivariable model did not impact the primary outcome (aHR 0.62: 95% CI: 0.19–2.01), or decrease the impact of COVID-19 severity (aHR: 3.39, 95% CI: 0.40–1.31).

| Table 1. Demographics, baseline IBD characteristics. |
|---------------------------------------------------|
| Controls (non-COVID-19) N=251 | Cases (COVID-19 positive) N=251 | p Value |
| Demographics | | | |
| Age (years) | 38 [30, 53] | 39 [29, 52] | 0.79 |
| Male sex | 114 [45] | 114 [45] | matched |
| Caucasian race | 213 [85] | 204 [83] | 0.41 |
| Non-hispanic ethnicity | 199 [94] | 183 [90] | 0.11 |
| Current smoker | 10 [4] | 8 [3] | 0.61 |
| IBD characteristics | | | |
| UC | 112 [45] | 112 [45] | matched |
| Extensive colitis | 61 [55] | 56 [50] | 0.68 |
| CD | 139 [55] | 139 [55] | matched |
| Ileocolonic | 55 [40] | 58 [42] | 0.67 |
| Penetrating/stricturing | 45 [38] | 61 [49] | 0.09 |
| Perianal | 21 [15] | 19 [14] | 0.73 |
| Duration of IBD (years) | 12.7 ± 10.3 | 12.8 ± 10.6 | 0.99 |
| Prior IBD surgery | 60 [24] | 63 [25] | 0.76 |
| Prior IBD hospitalization | 67 [27] | 90 [36] | 0.03 |
| Medication history | | | |
| Aminosalicylate | 191 [78] | 196 [80] | 0.81 |
| Corticosteroid | 164 [65] | 188 [75] | 0.06 |
| 6MP/Azathioprine | 72 [29] | 76 [30] | 0.67 |
| Any biologic | 160 [64] | 182 [73] | 0.04 |
| TNF-antagonist | 130 [52] | 155 [62] | 0.17 |
| Vedolizumab | 51 [20] | 57 [23] | 0.80 |
| Ustekinumab | 43 [17] | 36 [14] | 0.61 |

Proportions reported as no. [%]. Continuous variables reported as mean ± SD or median [IQR]. CD, Crohn’s disease; IBD, inflammatory bowel disease; IQR, interquartile range; SD, standard deviation; TNF, tumor necrosis factor; UC, ulcerative colitis.
Table 2. Long-term outcomes in COVID-19 and IBD.

| Outcome                                      | Controls (non-COVID-19) N = 251 | Cases (COVID-19 positive) N = 251 | p value  |
|----------------------------------------------|---------------------------------|-----------------------------------|----------|
| Primary outcomes                             |                                 |                                   |          |
| Composite outcome                            |                                 |                                   |          |
| IBD-related hospitalization                  | 38 (15)                         | 29 (12)                           | 0.24     |
| At 90 days                                   | 5 (2)                           | 8 (3)                             | 0.40     |
| At 1 year                                    | 25 (10)                         | 19 (8)                            | 0.34     |
| IBD-related surgery hospitalization          | 21 (8)                          | 14 (6)                            | 0.22     |
| At 90 days                                   | 6 (2)                           | 3 (1)                             | 0.31     |
| At 1 year                                    | 20 (8)                          | 9 (4)                             | 0.04     |
| Secondary outcomes                           |                                 |                                   |          |
| Change in therapy                            |                                 |                                   |          |
| Dose escalation of prior biologic            | 15 (12)                         | 13 (10)                           | 0.58     |
| Switch to new agent                          | 65 (26)                         | 51 (20)                           | 0.14     |
| Initiation of steroids                       | 42 (17)                         | 30 (12)                           | 0.13     |
| Disease progression                          |                                 |                                   |          |
| Progression of UC extent                     | 4 (4)                           | 5 (5)                             | 0.73     |
| Change in CD location                        | 1 (1)                           | 1 (1)                             | 1.00     |
| Change in CD behavior                        | 14 (10)                         | 14 (10)                           | 1.00     |
| Non-IBD complications                        |                                 |                                   |          |
| New non-IBD IMID                             | 0                               | 1 (1)                             | 0.32     |
| New establishment of psych care              | 6 (2)                           | 5 (2)                             | 0.76     |
| New anti-psych med                           | 7 (3)                           | 6 (2)                             | 0.78     |
| Interval COVID-19                            | 7 (3)                           | 1 (1)                             | 0.03     |
| Follow-up characteristics                    |                                 |                                   |          |
| Time to first follow-up visit                | 79 (35, 139)                    | 64 (29, 127)                      | 0.22     |
| First follow-up via telehealth               | 136 [54]                        | 174 [69]                          | <0.001   |
| Mean no. of follow-ups                       | 4.8 ± 3.3                       | 4.3 ± 4.3                         | 0.09     |
| Total duration of follow-up (person-days)    | 386.9                           | 344.4                             | N/A      |
| COVID-19 vaccine received                    | 186 (74)                        | 128 (51)                          | <0.001   |

Proportions reported as no. (%). Continuous variables reported as mean ± SD or median [IQR].
CD, Crohn's disease; COVID-19, coronavirus disease 2019; IBD, inflammatory bowel disease; IMID, immune-mediated inflammatory disease; IQR, interquartile range; SD, standard deviation; UC, ulcerative colitis.
In this multicenter, case–control, prospective observational cohort of IBD patients from five academic centers in the New York City area, COVID-19 was not associated with long-term worsening of disease course of IBD, defined as subsequent need for hospitalization, surgery, or other non-IBD adverse outcomes such as the development of other IMIDs or psychiatric comorbidities. However, severe COVID-19 did appear to increase the risk of future adverse IBD outcomes. This is the largest study to date to assess the long-term impact of COVID-19 in IBD and the first to use a case–control, matched study design, to specifically determine the independent effect of COVID-19 on the course of IBD.

Reassuring early data from New York City, the epicenter of the COVID-19 pandemic in the United States, showed that the majority of COVID-19 cases in patients with IBD were mild-to-moderate and not associated with poor outcomes. The international SECURE-IBD

![Figure 1. Kaplan–Meier curve of IBD hospitalizations or surgeries over time. Log-rank \( p = 0.70 \). IBD, inflammatory bowel disease.](image)

### Table 3. Multivariate cox proportional analysis of risk factors for composite outcome of IBD hospitalization or surgery.*

| Risk factors                              | aHR* (95% CI)  | \( p \) Value |
|-------------------------------------------|----------------|--------------|
| COVID-19                                  | 0.84 (0.44–1.42) | 0.43         |
| Prior IBD hospitalization or surgery      | 2.71 (1.53–4.80) | <0.01        |
| Penetrating or strictureing CD            | 1.41 (0.78–2.54) | 0.26         |
| Extensive or pan UC                      | 1.79 (0.87–3.69) | 0.11         |
| Current steroid use                      | 2.09 (0.98–4.78) | 0.06         |
| Biologic or novel small molecule exposure | 1.24 (0.67–2.32) | 0.49         |
| Biologic delay due to COVID-19            | 0.78 (0.32–1.86) | 0.78         |
| Time to first follow-up after study entry| 0.99 (0.99–1.00) | 0.38         |

*All variables included in the Cox proportional hazards regression model are reported in the table.

CD, Crohn’s disease; COVID-19, coronavirus disease 2019; IBD, inflammatory bowel disease; ICU, intensive care unit; UC, ulcerative colitis.

**Discussion**

In this multicenter, case–control, prospective observational cohort of IBD patients from five academic centers in the New York City area, COVID-19 was not associated with long-term worsening of disease course of IBD, defined as subsequent need for hospitalization, surgery, or other non-IBD adverse outcomes such as the development of other IMIDs or psychiatric comorbidities. However, severe COVID-19 did appear to increase the risk of future adverse IBD outcomes. This is the largest study to date to assess the long-term impact of COVID-19 in IBD and the first to use a case–control, matched study design, to specifically determine the independent effect of COVID-19 on the course of IBD.

Reassuring early data from New York City, the epicenter of the COVID-19 pandemic in the United States, showed that the majority of COVID-19 cases in patients with IBD were mild-to-moderate and not associated with poor outcomes.
(Surveillance Epidemiology of Coronavirus Under Research Exclusion) registry confirmed this at a global level, although a more recent population-based study by Attauabi et al.8 did show that patients with IBD have worse COVID-19 outcomes.9,10,24 When assessing the impact of COVID-19 on IBD, Lukin et al.25 found that patients with IBD and COVID-19 did not have worsening of their IBD clinical disease activity, endoscopic scores or biomarkers of inflammation up to 210 days after infection.

Although our study similarly showed overall non-severe outcomes in patients with COVID-19 and IBD, when stratified by infection severity, the subgroup of patients with severe COVID-19 had numerically increased rates of future IBD-related hospitalization or surgery, hospitalization at 1 year, surgery at 1 year, and initiation of new biologic agent (Supplemental Table 3). These findings are notable but should be interpreted with caution in this smaller sample. It is possible that severe COVID-19 is a reflection of, rather than risk factor for, uncontrolled IBD as studies have shown that baseline steroid use and disease activity are associated with worse COVID-19 outcomes.5,26 Delays in care or postponement of biologics due to COVID-19 may also lead to worse IBD outcomes, as has been reported in one study by Li et al.27 We demonstrate, however, that transient postponement of biologics in the setting of COVID-19 did not have an adverse impact on IBD outcomes. On the other hand, administration of COVID-19-related therapies did not appear to mitigate the risk of future adverse IBD outcomes.

After multivariable analysis adjusting for various indicators of disease activity and delays in care, COVID-19 was not an independent risk factor for subsequent IBD-related hospitalization or surgery. This especially notable given that the COVID-19 cases in our study had more severe IBD at baseline, with higher rates of penetrating or stricturing CD, prior hospitalizations, steroid use, and biologic use. This suggests that COVID-19 alone does not appear to alter the future course of IBD. However, patients who experience a severe course of COVID-19 and its resultant hyper-inflammatory cytokine storm may potentially have worse future IBD outcomes, although this requires further study.28

Table 4. Subgroup analysis: multivariate cox proportional analysis of risk factors for composite outcome of IBD hospitalization or surgery, stratified by COVID-19 severity.*

| Risk factors                                    | aHR* (95% CI)   | p Value |
|-------------------------------------------------|-----------------|---------|
| Severe COVID-19**                               | 2.43 (1.00–5.86)| 0.05    |
| Non-severe COVID-19                             | 0.68 (0.38–1.23)| 0.20    |
| Prior IBD hospitalization or surgery            | 2.56 (1.46–4.58)| <0.01   |
| Penetrating or stricturing CD                   | 1.83 (0.98–3.42)| 0.06    |
| Extensive or pan UC                            | 1.56 (0.85–2.80)| 0.15    |
| Current steroid use                             | 1.91 (0.89–4.08)| 0.10    |
| Biologic or novel small molecule exposure       | 1.24 (0.67–2.32)| 0.69    |
| Biologic delay due to COVID-19 infection        | 0.73 (0.30–1.76)| 0.48    |
| Time to first follow-up after study entry       | 0.99 (0.99–1.00)| 0.32    |

*All variables included in the Cox proportional hazards regression model are reported in the table.

**COVID-19 course requiring hospitalization, oxygen supplementation, mechanical ventilation, or ICU admission.

CD, Crohn’s disease; COVID-19, coronavirus disease 2019; IBD, inflammatory bowel disease; ICU, intensive care unit; UC, ulcerative colitis.

Our study has limitations, including the risk of misclassification, as patients may have had undocumented or undiagnosed COVID-19 despite our use of fairly stringent criteria for identification of controls. We defined outcomes as discrete events of hospitalization and surgery to ensure consistency of outcome assessment across all study sites, but it is possible that other outcomes such as clinical disease scores, biomarkers, and endoscopic disease activity which were not evaluated may have differed between study groups. Lastly, the entry period of this study spanning 2020 captured COVID-19 cases likely from the original SARS-CoV-2 B.1.1.7 variant (Alpha), but these findings may not reflect the transmission and virulence profiles of later emergent strains such as the B.1.617.2 (Delta) and B.1.1.529 (Omicron) variants.

Conclusion
In this multicenter study, COVID-19 did not alter the long-term course of IBD; however, severe COVID-19 may portend a worse IBD disease course and prognosis. Risk mitigation and
vaccination remain important strategies in the care of IBD patients during the ongoing COVID-19 pandemic.

Declarations

Ethics approval and consent to participate
Local institutional review board approval with a waiver of informed consent was obtained at all centers included in this study (NYU Grossman School of Medicine IRB, s20-00873). This study was also conducted in accordance with the ethical principles of the Declaration of Helsinki.

Consent for publication
This publication was approved by all authors.

Author contribution[s]

Simon J. Hong: Conceptualization; Data curation; Formal analysis; Methodology; Writing – original draft; Writing – review & editing.

Sumona Bhattacharya: Data curation; Writing – review & editing.

Aiya Aboubakr: Data curation; Writing – review & editing.

Devika Nadkarni: Data curation; Writing – review & editing.

Diana Lech: Data curation; Writing – review & editing.

Ryan C. Ungaro: Methodology; Writing – review & editing.

Manasi Agrawal: Methodology; Writing – review & editing.

Robert P. Hirten: Methodology; Writing – review & editing.

Ruby Greywoode: Data curation; Writing – review & editing.

Anjali Mone: Writing – review & editing.

Shannon Chang: Data curation; Writing – review & editing.

David P. Hudesman: Data curation; Writing – review & editing.

Thomas Ullman: Writing – review & editing.

Keith Sultan: Writing – review & editing.

Dana J. Lukin: Methodology; Writing – review & editing.

Jean-Frederic Colombel: Conceptualization; Methodology; Writing – review & editing.

Jordan E. Axelrad: Conceptualization; Formal analysis; Methodology; Supervision; Writing – review & editing.

Acknowledgements
Not applicable.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Ryan C. Ungaro receives research support from the NIH NIDDK K23KD111995-01A1. Manasi Agrawal receives research support from the NIH NIDDK K23DK129762-01. Robert Hirten receives research support from the NIH NIDDK K23DK129835. Jordan Axelrad receives research support from the Crohn’s and Colitis Foundation, the Judith & Stewart Colton Center for Autoimmunity, Lyanne and Michael Saperstein, and the NIH NIDDK Diseases K23DK124570.

Competing interests
Simon J. Hong, Sumona Bhattacharya, Aiya Aboubakr, Devika Nadkarni, Diana Lech, Ruby Greywoode, Anjali Mone, and Thomas Ullman have no disclosures.

Ryan C. Ungaro has served as an advisory board member or consultant for AbbVie, Bristol Myers Squibb, Janssen, Pfizer, and Takeda; research support from AbbVie, Boehringer Ingelheim, Eli Lilly, and Pfizer.

Shannon Chang has served as a consultant for Shire, Pfizer, and Oshi Health.

David P. Hudesman has received research grants from Pfizer; served as a consultant for AbbVie, BMS, Janssen, Takeda, Pfizer, and Samsung.

Keith Sultan has received research funding from AbbVie, BMS, and Takeda.

Dana J. Lukin has served as a consultant for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Palatin Technologies, Pfizer; served as a speaker for AbbVie; and received research grants from AbbVie, Janssen, Takeda, Kenneth Rainin Foundation.

Jean-Frederic Colombel has received research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; receiving payment for lectures from
AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Glaxo Smith Kline, Geneva, Iterative Scopes, Janssen Pharmaceuticals, Kaleido Biosciences, Landos, Otsuka, Pfizer, Prometheus, Sanofi, Takeda, TiGenix; and hold stock options in Intestinal Biotech Development.

Jordan E. Axelrad has received research grants from BioFire Diagnostics; consultancy fees, honorarium, or advisory board fees from BioFire Diagnostics, Janssen, and Abbvie; and holds U.S. patent 2012/0052124A1.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

ORCID iDs
Simon J. Hong https://orcid.org/0000-0003-3802-1053
Shannon Chang https://orcid.org/0000-0001-6195-5386
Dana J. Lukin https://orcid.org/0000-0003-4581-2267
Jordan E. Axelrad https://orcid.org/0000-0003-1951-7790

Supplemental material
Supplemental material for this article is available online.

References
1. Dong E, Du H and Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; 20: 533–534.
2. Rubin DT, Abreu MT, Rai V, et al. Management of patients with Crohn’s disease and ulcerative colitis during the coronavirus disease-2019 pandemic: results of an international meeting. Gastroenterology 2020; 159: 6.e6–13.e6.
3. Aziz M, Fatima R, Haghbin H, et al. The incidence and outcomes of COVID-19 in IBD patients: a rapid review and meta-analysis. Inflamm Bowel Dis 2020; 26: e132–e133.
4. Allocca M, Fiorino G, Zallot C, et al. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the nancy and milan cohorts. Clin Gastroenterol Hepatol 2020; 18: 2134–2135.
5. Axelrad JE, Malter L, Hong S, et al. From the American epicenter: coronavirus disease 2019 in patients with inflammatory bowel disease in the New York City metropolitan area. Inflamm Bowel Dis 2021; 27: 662–666.
6. Singh S, Khan A, Chowdhry M, et al. Risk of severe coronavirus disease 2019 in patients with inflammatory bowel disease in the United States: a multicenter research network study. Gastroenterology 2020; 159: 1575.e4–1578.e4.
7. Zabana Y, Marin-Jiménez I, Rodriguez-Lago I, et al. Nationwide COVID-19-EII study: incidence, environmental risk factors and long-term follow-up of patients with inflammatory bowel disease and COVID-19 of the ENEIDA registry. J Clin Med 2022; 11: 421.
8. Attuabi M, Dahlerup JF, Poulsen A, et al. Association between the clinical, biochemical, and endoscopic activity of inflammatory bowel diseases and severity and long-term outcomes of coronavirus disease 2019-a population-based study. Inflamm Bowel Dis 2022; 28: 1618–1622.
9. Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 2020; 159: 481.e3–491.e3.
10. Agrawal M, Zhang X, Brenner EJ, et al. The impact of vedolizumab on COVID-19 outcomes among adult IBD patients in the SECURE-IBD registry. J Crohns Colitis 2021; 15: 1877–1884.
11. Rotshild V, Hirsh-Raccab B, Miskin I, et al. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep 2021; 11: 22777.
12. Lev-Tzion R, Focht G, Lujan R, et al. COVID-19 vaccine is effective in inflammatory bowel disease patients and is not associated with disease exacerbation. Clin Gastroenterol Hepatol 2022; 20: e1263–e1282.
13. Ngai JC, Ko FW, Ng SS, et al. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology 2010; 15: 543–550.
14. Lam MH-B, Wing Y-K, Yu MW-M, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term...
follow-up. *Arch Intern Med* 2009; 169: 2142–2147.

15. Wang F, Kream RM and Stefano GB. Long-term respiratory and neurological sequelae of COVID-19. *Med Sci Monit* 2020; 26: e928996.

16. Vanichkachorn G, Newcomb R, Cowl CT, et al. Post-COVID-19 syndrome (long haul syndrome): description of a multidisciplinary clinic at mayo clinic and characteristics of the initial patient cohort. *Mayo Clin Proc* 2021; 96: 1782–1791.

17. Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. *Nat Immunol* 2022; 23: 210–216.

18. Mehandru S and Merad M. Pathological sequelae of long-haul COVID. *Nat Immunol* 2022; 23: 194–202.

19. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. *Nature* 2021; 591: 639–644.

20. Luo X-H, Zhu Y, Mao J, et al. T cell immunobiology and cytokine storm of COVID-19. *Scan J Immunol* 2021; 93: e12989.

21. Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. *Gut* 2021; 70: 725–732.

22. Meyer A, Semenzato L, Zureik M, et al. Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study. *Aliment Pharmacol Ther* 2021; 54: 160–166.

23. Elm E von, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007; 147: 573–577.

24. Attuabi M, Dahlerup JF, Poulsen A, et al. Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases - a Danish prospective population-based cohort study with individual-level data. *J Crohns Colitis* 2022; 16: 757–767.

25. Lukin DJ, Funez-dePagnier G, Lima S, et al. No durable impact of COVID-19 on intestinal disease activity in subjects with IBD. *Clin Gastroenterol Hepatol* 2021; 19: 2312.e3–2314.e3.

26. Lukin DJ, Kumar A, Hajifathalian K, et al. Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease. *Gastroenterology* 2020; 159: 1541.e2–1544.e2.

27. Li Y, Chen L, Chen S, et al. Delayed infliximab treatment affects the outcomes of patients with Crohn’s disease during the COVID-19 epidemic in China: a propensity score-matched analysis. *Front Med (Lausanne)* 2021; 8: 819557.

28. Faigenbaum DC and June CH. Cytokine storm. *N Engl J Med* 2020; 383: 2255–2273.